FXR Agonists for Dyslipidemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and related diseases, such as atherosclerosis and diabetes, lack potent, efficacious, and selective farnesoid X receptor (FXR) agonists that can effectively modulate plasma lipids like triglycerides, HDL cholesterol, and LDL cholesterol.
Innovation Solution
Development of novel compounds that act as potent, efficacious, and selective FXR agonists, specifically formulated to alter lipid profiles by lowering total cholesterol, LDL cholesterol, raising HDL levels, and reducing triglycerides, thereby treating dyslipidemia and related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for dyslipidemia, then current therapeutic options are available, but they lack potency, efficacy, and selectivity as FXR agonists
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters (substituents at positions R1-R7, ring structures Ar1, and linkers L1) to optimize FXR binding affinity and selectivity. This involves changing molecular weight, lipophilicity, and steric parameters to achieve potent and selective FXR agonism while avoiding off-target effects.
Solution Approach 2:
The invention segments the FXR agonist molecule into distinct functional regions (Ar1 aromatic core, L1 linker, R1-R7 substituents) that can be independently optimized. This modular approach allows separate optimization of binding affinity (through Ar1-L1 interactions) and selectivity (through specific R-group interactions with FXR subsites).
2Reliability
If novel FXR agonist compounds are developed, then potent and selective lipid modulation is achieved, but extensive structural optimization and screening are required
Solution Approach 1:
The patent establishes a universal scaffold (Ar1-L1-R core structure) that can perform multiple functions: binding to FXR, inducing conformational change for selectivity, and providing points for lipid-modulating substituents. This multi-functional design reduces the need for extensive optimization of separate binding and selectivity elements.
Solution Approach 2:
The invention creates composite molecular structures combining aromatic cores (Ar1), flexible linkers (L1), and functional substituents (R1-R7) that work synergistically. This composite approach integrates multiple structural elements into a unified agonist molecule that achieves both potency and selectivity through coordinated interactions with FXR.
Data Source
AI summary
Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.